Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
09/2003
09/25/2003WO2003077914A1 N3 alkylated benzimidazole derivatives as mek inhibitors
09/25/2003WO2003077904A1 Biological activity-promoting compositions containing soybean germ-origin isoflavone aglycon
09/25/2003WO2003077890A1 Hormone-containing transdermal therapeutic system with an active substance reservoir based on vinylacetate-vinylpyrrolidone copolymer with improved cohesion.
09/25/2003WO2003077847A2 Substituted amides
09/25/2003WO2003077832A2 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003WO2003068171A3 Method and composition for treatment of inflammation and aids-associated neurological disorders
09/25/2003WO2003042411A3 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease
09/25/2003WO2003042245B1 Growth hormone variations in humans and their uses
09/25/2003WO2003039472A3 Intraorally disintegrating valdecoxib compositions prepared by fluid bed granulation process
09/25/2003WO2003039451A3 Thiazole pyridazinones as adenosine antagonists
09/25/2003WO2003029199A9 Benzene derivatives, process for preparing the same and use thereof
09/25/2003WO2003013530A3 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives as nmda antagonists
09/25/2003WO2003002108A3 Use of tyrosine kinase inhibitors for treating inflammatory diseases
09/25/2003WO2002100412A3 Stabilized dispersion of phytosterol in oil
09/25/2003WO2002096357A3 Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
09/25/2003WO2002094287A3 Identifying parasitic fungi of the organism, and treatment thereof
09/25/2003WO2002074733A3 Tryptase-inhibitors
09/25/2003WO2002064634A3 Human monoclonal antibodies to fc alpha receptor (cd89)
09/25/2003WO2002017789A3 Methods and devices for quantitative analysis of x-ray images
09/25/2003US20030181728 Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
09/25/2003US20030181587 Thermoplastic resin composition
09/25/2003US20030181519 Substituted phenyl naphthalenes as estrogenic agents
09/25/2003US20030181515 Administering to a subject in need of pain relief a medicinal ointment comprising an active kavalactone selected from the group consisting of dihydrokawain, dihydromethysticin, kawain and medicinally acceptable carrier
09/25/2003US20030181514 Therapeutic compounds and methods
09/25/2003US20030181498 For therapy of disease mediated by interation of Vascular Cell Adhesion Molecule-1 (VCAM-1) and/or fibronectin and integrin receptor and/or alpha 4 beta 1
09/25/2003US20030181497 Heterocyclic acridone inhibitors of IMPDH enzyme
09/25/2003US20030181481 Therapeutic drugs for treating central nervous system disorders
09/25/2003US20030181477 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor
09/25/2003US20030181476 Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use thereof
09/25/2003US20030181443 Aminothiolester compounds, pharmaceutical and cosmetic compositions containing same and uses thereof
09/25/2003US20030181441 Tumor necrosis factor-alpha converting enzyme antagonists, such as (2S,3S)-4-(4-(3,5-difluro-benzyloxy)-benzenesulfonyl) -2-methyl-thiomorpholine-3-carboxylic acid hydroxyamide, used as antiarthritic or anticarcinogenic agents
09/25/2003US20030181421 Method of administering bisphosphonates
09/25/2003US20030181418 Pharmaceutical composition
09/25/2003US20030181411 Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer
09/25/2003US20030181388 Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire
09/25/2003US20030181379 Novel fibroblast growth factor (FGF23) and methods for use
09/25/2003US20030181373 Vascular relaxation inhibitors. Vascular relaxation agents comprising PTHrP or a fragment thereof and vascular relaxation inhibitors comprising a substance capable of inhibiting the binding between PTHrP and a receptor thereof.
09/25/2003US20030181362 Receptor
09/25/2003US20030181352 Substituted heterocyclic compounds
09/25/2003US20030180934 Plasminogen-like polynucleotides, polypeptides, and antibodies
09/25/2003US20030180877 Gene therapy; drug screening
09/25/2003US20030180805 Methods and compositions for derepression of IAP-inhibited caspase
09/25/2003US20030180752 Type 2 cytokine receptor and nucleic acids encoding same
09/25/2003US20030180402 Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from Acacia
09/25/2003US20030180394 Extracts from sophora species, method for producing the same and their use
09/25/2003US20030180386 Aqueous metal bicarbonate solution and method of use
09/25/2003US20030180348 Transcellular drug delivery system
09/25/2003US20030180306 Controlling cell differentiation; muscular disorders
09/25/2003US20030180300 Collagen biosynthesis; controlling cell differentiation, cell proliferation
09/25/2003US20030180288 Methods and compositions for modulating immune response and for the treatment of inflammatory disease
09/25/2003US20030180287 Polypeptide formulation
09/25/2003US20030180275 Human serpin polypeptides
09/25/2003US20030180274 Skin disorders; bone defects; administering mixture of blood platelet and calcium phosphate
09/25/2003US20030180269 Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
09/25/2003US20030180265 Modulating angiogenesis
09/25/2003US20030180253 Stabilized liquid polypeptide-containing pharmaceutical compositions
09/25/2003CA2479676A1 Dexanabinol and dexanabinol analogs regulate inflammation related genes
09/25/2003CA2478803A1 Methods of modulating cd200 receptors
09/25/2003CA2478795A1 Use of rapamycin for inhibiting cell death
09/25/2003CA2478715A1 Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
09/24/2003EP1346982A1 Vla-4 inhibitors
09/24/2003EP1346061A2 Pregnancy-associated plasma protein-a2 (papp-a2)
09/24/2003EP1346042A2 Fat regulated genes, uses thereof, and compounds for modulating same
09/24/2003EP1346031A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof
09/24/2003EP1345946A1 Macroheterocylic compounds useful as kinase inhibitors
09/24/2003EP1345938A1 Tricyclic crf receptor antagonists
09/24/2003EP1345933A2 Process for making substituted 8-arylquinolinium benzenesulfonate
09/24/2003EP1345929A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345928A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345927A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345926A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345925A2 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345922A1 Pyrazole compounds useful as protein kinase inhibitors
09/24/2003EP1345914A1 Therapeutic compounds
09/24/2003EP1345909A1 Phenylacetamido-pyrazole derivatives and their use as antitumor agents
09/24/2003EP1345899A1 Compounds
09/24/2003EP1345898A2 Teracyclic carbazole derivates and their use as spla2 inhibitors
09/24/2003EP1345612A1 Use of low molecular heparin for treating osteoarthritis
09/24/2003EP1345609A1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
09/24/2003EP1345603A1 (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
09/24/2003EP1345598A2 The use of ppar-gamma agonists for treating diseases characterised by neuron degeneration, neuron injury or impaired plasticity
09/24/2003EP1259512B1 Pteridine compounds for the treatment of psoriasis
09/24/2003EP1252163B1 4-pyridyl-and 2,4-pyrimidinyl-substituted pyrrole derivatives and their use in pharmacy
09/24/2003EP1242396B1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
09/24/2003EP1150953B1 Indole derivatives and their use as mcp-1 receptor antagonists
09/24/2003EP1124554B1 Pharmaceutical compositions containing tetrahydroisoquinoline compounds
09/24/2003EP1094829B1 Methods for accelerating bone and cartilage growth and repair
09/24/2003EP1080055B1 24-hydroxyvitamin d, analogs and uses thereof
09/24/2003EP0984959B1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
09/24/2003EP0904270B1 Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
09/24/2003EP0847278B1 Analogs of parathyroid hormone
09/24/2003CN1444654A Novel therapeutic molecular variants and uses thereof
09/24/2003CN1444597A 2-substituted pregna-1,3,5(10)-triene and chola-1,3,5(10)-triene derivatives and their biological activity
09/24/2003CN1444584A N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases
09/24/2003CN1444583A Method for preparing arylacetyl aminothiazole
09/24/2003CN1444573A Carboxamide compounds and their use as antagonists of human 11CBY receptor
09/24/2003CN1444572A 2-aminothiazoline derivatives and their use as no-synthase inhibitors
09/24/2003CN1444570A Non-steroidal inflammation inhibitors
09/24/2003CN1444566A Imidazolyl derivatives
09/24/2003CN1444563A Quinoline and quinazoline derivatives
1 ... 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 ... 820